FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006962325> ?p ?o ?g. }

• W2006962325 endingPage "1315" @default.
• W2006962325 startingPage "1315" @default.
• W2006962325 abstract "To the Editor:Adenosine deaminase (ADA) is a predominant T-lymphocyte enzyme, and its plasma activity is high in diseases where cellular immunity is stimulated. Acute pneumonia due to Mycoplasma pneumoniae may be related to T-lymphocytes activity,1Biberfeld G. Biberfeld P. Sterner G. Cell-mediated immune response following Mycoplasma pneumonia infection in man.Clin Exp Immunol. 1974; 17: 29-41PubMed Google Scholar, 2Taylor-Robinson D. Denny F.W. Allison A.C. Thompson G.W. Taylor G. Cell-mediated immunity and the response to mycoplasma infections.in: A Ciba Foundation symposium. Pathogenic mycoplasmas. Elsevier Scientific Publishing Co, Amsterdam1972: 349-362Crossref Google Scholar and is different from bacterial pneumonia in its inflammatory process. It is sometimes difficult to clinically diagnose mycoplasma pneumonia in the early stage, before the rise of antibody titer to Mycoplasma pneumoniae, β-lactam group antibiotic therapy, which is most commonly used in pneumonia, is not effective on mycoplasma pneumonia. If mycoplasma pneumonia is diagnosed in the early stage, antibiotic therapy could be more effective with erythromycin or tetracycline.In this study, we have investigated 32 cases with pneumonia (12 cases of mycoplasma pneumonia and 20 cases of bacterial pneumonia) to see the usefulness of ADA measurement in the diagnosis of mycoplasma pneumonia.Twelve patients with mycoplasma pneumonia were diagnosed by rise of a complement fixing (CF) titer of antibody to Mycoplasma pneumoniae. Twenty patients with non-mycoplasma pneumonia did not show elevation of the CF titer, and were treated with β-lactam group antibiotics effectively. ADA activity was tested within ten days from the first symptoms in all cases. Measurements of ADA activity in sera were done by the method of Giusti.3Giusti G. Adenosine deaminase.in: Bergmeyer H.U. Methods of enzymatic analysis. Academic Press Inc, New York1974Crossref Google ScholarSerum ADA activity in the group with mycoplasma pneumonia was 30.2 ± 14.0 U/I (37° C), that of non-mycoplasma pneumonia patients 12.5 ± 3.3, and that of normal control subjects 15.2 ± 4.5 (Fig 1). ADA activity of the group with mycoplasma pneumonia was significantly higher than those with non-mycoplasma pneumonia and normal control subjects (p<0.001).If the inflammatory process of mycoplasma pneumonia is mainly dependent on T-cell lymphocyte activities, it seems reasonable that serum ADA activity shows high level in this disease but not in bacterial pneumonia. These results suggest that serum ADA activity in patients with acute pneumonia may be useful for the early diagnosis of pneumonia due to Mycoplasma pneumoniae. To the Editor: Adenosine deaminase (ADA) is a predominant T-lymphocyte enzyme, and its plasma activity is high in diseases where cellular immunity is stimulated. Acute pneumonia due to Mycoplasma pneumoniae may be related to T-lymphocytes activity,1Biberfeld G. Biberfeld P. Sterner G. Cell-mediated immune response following Mycoplasma pneumonia infection in man.Clin Exp Immunol. 1974; 17: 29-41PubMed Google Scholar, 2Taylor-Robinson D. Denny F.W. Allison A.C. Thompson G.W. Taylor G. Cell-mediated immunity and the response to mycoplasma infections.in: A Ciba Foundation symposium. Pathogenic mycoplasmas. Elsevier Scientific Publishing Co, Amsterdam1972: 349-362Crossref Google Scholar and is different from bacterial pneumonia in its inflammatory process. It is sometimes difficult to clinically diagnose mycoplasma pneumonia in the early stage, before the rise of antibody titer to Mycoplasma pneumoniae, β-lactam group antibiotic therapy, which is most commonly used in pneumonia, is not effective on mycoplasma pneumonia. If mycoplasma pneumonia is diagnosed in the early stage, antibiotic therapy could be more effective with erythromycin or tetracycline. In this study, we have investigated 32 cases with pneumonia (12 cases of mycoplasma pneumonia and 20 cases of bacterial pneumonia) to see the usefulness of ADA measurement in the diagnosis of mycoplasma pneumonia. Twelve patients with mycoplasma pneumonia were diagnosed by rise of a complement fixing (CF) titer of antibody to Mycoplasma pneumoniae. Twenty patients with non-mycoplasma pneumonia did not show elevation of the CF titer, and were treated with β-lactam group antibiotics effectively. ADA activity was tested within ten days from the first symptoms in all cases. Measurements of ADA activity in sera were done by the method of Giusti.3Giusti G. Adenosine deaminase.in: Bergmeyer H.U. Methods of enzymatic analysis. Academic Press Inc, New York1974Crossref Google Scholar Serum ADA activity in the group with mycoplasma pneumonia was 30.2 ± 14.0 U/I (37° C), that of non-mycoplasma pneumonia patients 12.5 ± 3.3, and that of normal control subjects 15.2 ± 4.5 (Fig 1). ADA activity of the group with mycoplasma pneumonia was significantly higher than those with non-mycoplasma pneumonia and normal control subjects (p<0.001). If the inflammatory process of mycoplasma pneumonia is mainly dependent on T-cell lymphocyte activities, it seems reasonable that serum ADA activity shows high level in this disease but not in bacterial pneumonia. These results suggest that serum ADA activity in patients with acute pneumonia may be useful for the early diagnosis of pneumonia due to Mycoplasma pneumoniae." @default.
• W2006962325 created "2016-06-24" @default.
• W2006962325 creator A5000589488 @default.
• W2006962325 creator A5001859263 @default.
• W2006962325 creator A5055477781 @default.
• W2006962325 creator A5072513046 @default.
• W2006962325 creator A5089636779 @default.
• W2006962325 date "1988-12-01" @default.
• W2006962325 modified "2023-09-27" @default.
• W2006962325 title "Serum Adenosine Deaminase Activity with Mycoplasma pneumoniae" @default.
• W2006962325 cites W126670255 @default.
• W2006962325 cites W1566830427 @default.
• W2006962325 cites W2141892789 @default.
• W2006962325 doi "https://doi.org/10.1378/chest.94.6.1315a" @default.
• W2006962325 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3191780" @default.
• W2006962325 hasPublicationYear "1988" @default.
• W2006962325 type Work @default.
• W2006962325 sameAs 2006962325 @default.
• W2006962325 citedByCount "12" @default.
• W2006962325 countsByYear W20069623252021 @default.
• W2006962325 countsByYear W20069623252022 @default.
• W2006962325 crossrefType "journal-article" @default.
• W2006962325 hasAuthorship W2006962325A5000589488 @default.
• W2006962325 hasAuthorship W2006962325A5001859263 @default.
• W2006962325 hasAuthorship W2006962325A5055477781 @default.
• W2006962325 hasAuthorship W2006962325A5072513046 @default.
• W2006962325 hasAuthorship W2006962325A5089636779 @default.
• W2006962325 hasBestOaLocation W20069623251 @default.
• W2006962325 hasConcept C126322002 @default.
• W2006962325 hasConcept C203014093 @default.
• W2006962325 hasConcept C2776345407 @default.
• W2006962325 hasConcept C2777914695 @default.
• W2006962325 hasConcept C2778838687 @default.
• W2006962325 hasConcept C2779215961 @default.
• W2006962325 hasConcept C2779706735 @default.
• W2006962325 hasConcept C501593827 @default.
• W2006962325 hasConcept C71924100 @default.
• W2006962325 hasConcept C86803240 @default.
• W2006962325 hasConcept C89423630 @default.
• W2006962325 hasConceptScore W2006962325C126322002 @default.
• W2006962325 hasConceptScore W2006962325C203014093 @default.
• W2006962325 hasConceptScore W2006962325C2776345407 @default.
• W2006962325 hasConceptScore W2006962325C2777914695 @default.
• W2006962325 hasConceptScore W2006962325C2778838687 @default.
• W2006962325 hasConceptScore W2006962325C2779215961 @default.
• W2006962325 hasConceptScore W2006962325C2779706735 @default.
• W2006962325 hasConceptScore W2006962325C501593827 @default.
• W2006962325 hasConceptScore W2006962325C71924100 @default.
• W2006962325 hasConceptScore W2006962325C86803240 @default.
• W2006962325 hasConceptScore W2006962325C89423630 @default.
• W2006962325 hasIssue "6" @default.
• W2006962325 hasLocation W20069623251 @default.
• W2006962325 hasLocation W20069623252 @default.
• W2006962325 hasOpenAccess W2006962325 @default.
• W2006962325 hasPrimaryLocation W20069623251 @default.
• W2006962325 hasRelatedWork W2032723672 @default.
• W2006962325 hasRelatedWork W2351483331 @default.
• W2006962325 hasRelatedWork W2352345350 @default.
• W2006962325 hasRelatedWork W2355811776 @default.
• W2006962325 hasRelatedWork W2377393846 @default.
• W2006962325 hasRelatedWork W2396811040 @default.
• W2006962325 hasRelatedWork W2515882494 @default.
• W2006962325 hasRelatedWork W3029763930 @default.
• W2006962325 hasRelatedWork W3101753658 @default.
• W2006962325 hasRelatedWork W4313368331 @default.
• W2006962325 hasVolume "94" @default.
• W2006962325 isParatext "false" @default.
• W2006962325 isRetracted "false" @default.
• W2006962325 magId "2006962325" @default.
• W2006962325 workType "article" @default.